Severe symptoms interfering with work, social activities, or sleep warrant medical discussion even if no underlying pathology is identified
In summary, despite the challenges posed by tumour heterogeneity, diverse microenvironmental adaptability, and safety concerns, targeted therapies aimed at ROS and related PCD pathways offer new perspectives for precision medicine in breast cancer
PDA + GHK-Cu protocol: PDA: 500 mcg subcutaneous or oral, once daily GHK-Cu: Per standard dosing guidelines (varies by administration route) Duration: 4 to 8 weeks PDA + SS-31 (Elamipretide) For researchers focused on mitochondrial health and cellular energy, combining penta deca peptide arginate with SS-31 creates a protocol that addresses tissue repair from both structural and energetic perspectives
However, it is important to note that erythrocytes generate ROS primarily as a result of (i) hemoglobin oxidation, which can be considered as an iron-mediated Fenton reaction, (ii) the activity of NAPDH oxidase and (iii) xanthine oxidoreductase, while in nucleated cells ROS are mainly generated in the mitochondrial electron transport chain
